Molecular imaging for personalized cancer care

Molecular Oncology

Volumn 6, Issue 2, 2012, Pages 182-195

  Kircher, Moritz F ^a   Hricak, Hedvig ^a   Larson, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Diagnostics; Hyperpolarized MRI; Molecular imaging; MR spectroscopic imaging; MR PET; MRI; Oncology; Optical imaging; PET CT; PET MRI; Raman spectroscopy; Theranostics

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; 4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; ANDROGEN RECEPTOR ANTAGONIST; ANTIESTROGEN; BEVACIZUMAB; CETUXIMAB; CHOLINE C 11; DASATINIB; FIACITABINE; FLUORO DIHYDROTESTOSTERONE F 18; FLUOROAZOMYCIN ARABINOSIDE F 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; IMATINIB; PYRUVIC ACID C 13; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; THYMIDINE F 18; TIRAPAZAMINE; TRASTUZUMAB; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; HUMAN; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84860492393     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.02.005     Document Type: Review

References (125)

1. 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008, 68(20):8607-8615.
2. 31P MR spectroscopy in human cancer research. In vitro and normal volunteer studies. NMR Biomed. 2004, 17(6):382-391.
3. 31P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial. NMR Biomed. 2006, 19(4):504-512.
4. Bading J.R., Shields A.F. Imaging of cell proliferation: status and prospects. J. Nucl. Med. 2008, 49(Suppl. 2):64S-80S.
5. Benezra M., Penate-Medina O., Zanzonico P.B., et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J. Clin. Invest. 2011, 121(7):2768-2780.
6. Blackledge M.D., Leach M.O., Collins D.J., Koh D.M. Computed diffusion-weighted MR imaging may improve tumor detection. Radiology 2011.
7. Blankenberg F.G. In vivo imaging of apoptosis. Cancer Biol. Ther. 2008, 7(10):1525-1532.
8. Blankenberg F.G. Monitoring of treatment-induced apoptosis in oncology with PET and SPECT. Curr. Pharm. Des. 2008, 14(28):2974-2982.
9. Blum R., MacManus M.P., Rischin D., Michael M., Ball D., Hicks R.J. Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. Am. J. Clin. Oncol. 2004, 27(2):164-171.
10. Bole K. UCSF News Center. UCSF Web site. "Watchful Waiting" has a New Set of Eyes 2010, Available at:, (accessed on 30.9.11). http://www.ucsf.edu/news/2010/11/5846/new-prostate-cancer-imaging-shows-real-time-tumor-metabolism.
11. Bradbury M., Hricak H. Molecular MR imaging in oncology. Magn. Reson. Imaging Clin. N. Am. 2005, 13(2):225-240.
12. 31C magnetic resonance spectroscopy. Magn. Reson. Med. 2011, 66(2):505-519.
13. Buck A.K., Herrmann K., Stargardt T., Dechow T., Krause B.J., Schreyogg J. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J. Nucl. Med. 2010, 51(3):401-412.
14. Bury T., Dowlati A., Paulus P., et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur. Respir. J. 1996, 9(3):410-414.
15. Bussink J., Kaanders J.H., van der Graaf W.T., Oyen W.J. PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat. Rev. Clin. Oncol. 2011, 8(4):233-242.
16. Cai W., Chen X. Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 2008, 49(Suppl. 2):113S-128S.
17. Cai W., Niu G., Chen X. Imaging of integrins as biomarkers for tumor angiogenesis. Curr. Pharm. Des. 2008, 14(28):2943-2973.
18. Chan A.A., Lau A., Pirzkall A., et al. Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma. J. Neurosurg. 2004, 101(3):467-475.
19. Chun Y.S., Vauthey J.N. Extending the frontiers of resectability in advanced colorectal cancer. Eur. J. Surg. Oncol. 2007, 33(Suppl. 2):S52-S58.
20. Colen R.R., Kekhia H., Jolesz F.A. Multimodality intraoperative MRI for brain tumor surgery. Expert Rev. Neurother. 2010, 10(10):1545-1558.
21. Connell C.A., Corry J., Milner A.D., et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck 2007, 29(11):986-995.
22. Conti P.S., Bading J.R., Mouton P.P., Links J.M., Alauddin M.M., Fissekis J.D., et al. In vivo measurement of cell proliferation in canine brain tumor using C-11-labeled FMAU and PET. Nucl. Med. Biol. 2008, 35(1):131-141.
23. 13C magnetic resonance imaging and spectroscopy. Nat. Med. 2007, 13(11):1382-1387.
24. de Jong M., Breeman W.A., Kwekkeboom D.J., Valkema R., Krenning E.P. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc. Chem. Res. 2009, 42(7):873-880.
25. Dewhirst M.W., Sostman H.D., Leopold K.A., et al. Soft-tissue sarcomas: MR imaging and MR spectroscopy for prognosis and therapy monitoring. Work in progress. Radiology 1990, 174(3 Pt 1):847-853.
26. 31P magnetic resonance spectroscopy parameters and treatment outcome in patients with high-grade soft tissue sarcomas treated with thermoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61(2):480-491.
27. Downey R.J., Akhurst T., Gonen M., et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J. Clin. Oncol. 2004, 22(16):3255-3260.
28. 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75(4):1098-1104.
29. 18F-FDG PET in oncology. J. Nucl. Med. 2008, 49(3):480-508.
30. 13C-labelled bicarbonate. Nature 2008, 453(7197):940-943.
31. Gaster R.S., Hall D.A., Nielsen C.H., et al. Matrix-insensitive protein assays push the limits of biosensors in medicine. Nat. Med. 2009, 15(11):1327-1332.
32. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 2004, 4(11):891-899.
33. Glekas A.P., Pillarsetty N.K., Punzalan B., Khan N., Smith-Jones P., Larson S.M. In vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib. J. Nucl. Med. 2011, 52(8):1301-1307.
34. 13C. Br. J. Radiol. 2003, 76(2):S118-S127.
35. Grassi R., Lagalla R., Rotondo A. Genomics, proteomics, mems and saif: which role for diagnostic imaging?. La Radiolia Med. 2008, 113(6):775-778.
36. Graves E.E., Nelson S.J., Vigneron D.B., et al. A preliminary study of the prognostic value of proton magnetic resonance spectroscopic imaging in gamma knife radiosurgery of recurrent malignant gliomas. Neurosurgery 2000, 46(2):319-326. Discussion 26-8.
37. Grimm J., Kircher M.F., Weissleder R. Cell tracking. Principles and applications. Radiologe 2007, 47(1):25-33.
38. Gupta N., Gill H., Graeber G., Bishop H., Hurst J., Stephens T. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest 1998, 114(4):1105-1111.
39. Haglund M.M., Berger M.S., Hochman D.W. Enhanced optical imaging of human gliomas and tumor margins. Neurosurgery 1996, 38(2):308-317.
40. Haun J.B., Castro C.M., Wang R., et al. Micro-NMR for rapid molecular analysis of human tumor samples. Sci. Transl. Med. 2011, 3(71):71ra16.
41. 18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin. Cancer Res. 2007, 13(12):3552-3558.
42. Hicks R.J., Kalff V., MacManus M.P., et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J. Nucl. Med. 2001, 42(11):1605-1613.
43. Holland J.P., Caldas-Lopes E., Divilov V., et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS One 2010, 5(1):e8859.
44. Howe F.A., Maxwell R.J., Saunders D.E., Brown M.M., Griffiths J.R. Proton spectroscopy in vivo. Magn. Reson. Q. 1993, 9:31-59.
45. Hricak H. Oncologic imaging: a guiding hand of personalized cancer care. Radiology 2011, 259(3):633-640.
46. Juweid M.E., Cheson B.D. Positron-emission tomography and assessment of cancer therapy. N. Engl. J. Med. 2006, 354(5):496-507.
47. Juweid M.E., Stroobants S., Hoekstra O.S., et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J. Clin. Oncol. 2007, 25(5):571-578.
48. Kaanders J.H., Bussink J., van der Kogel A.J. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol. 2002, 3(12):728-737.
49. Kalff V., Hicks R.J., Ware R.E., Hogg A., Binns D., McKenzie A.F. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J. Nucl. Med. 2002, 43(4):492-499.
50. 18F]fluorothymidine positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 2007, 34(9):1339-1347.
51. Kircher, M.F., Willmann J.K. Molecular body imaging: MRI, CT and US. Part I - Principles, Radiology, in press-a.
52. Kircher M.F., Willmann J.K. Molecular body imaging: MRI, CT and US. Part II - Applications. Radiology, in press-b.
53. Kircher M.F., Josephson L., Weissleder R. Ratio imaging of enzyme activity using dual wavelength optical reporters. Mol. Imaging 2002, 1(2):89-95.
54. Kircher M.F., Allport J.R., Graves E.E., et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res. 2003, 63(20):6838-6846.
55. Kircher M.F., Mahmood U., King R.S., Weissleder R., Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res. 2003, 63(23):8122-8125.
56. Kircher M.F., Weissleder R., Josephson L. A dual fluorochrome probe for imaging proteases. Bioconjug. Chem. 2004, 15(2):242-248.
57. Kircher M.F., Grimm J., Swirski F.K., et al. Noninvasive in vivo imaging of monocyte trafficking to atherosclerotic lesions. Circulation 2008, 117(3):388-395.
58. Kircher M.F., Gambhir S.S., Grimm J. Noninvasive cell-tracking methods. Nat. Rev. Clin. Oncol. 2011, 8(11):677-688.
59. Kircher M.F., De la Zerda A., Jokerst J., et al. A brain tumor molecular imaging strategy using a novel triple-modality nanoparticle. Nat. Med., in press.
60. Koch A.M., Reynolds F., Kircher M.F., Merkle H.P., Weissleder R., Josephson L. Uptake and metabolism of a dual fluorochrome Tat-nanoparticle in HeLa cells. Bioconjug. Chem. 2003, 14(6):1115-1121.
61. Krohn K.A., Link J.M., Mason R.P. Molecular imaging of hypoxia. J. Nucl. Med. 2008, 49(Suppl 2.):129S-148S.
62. Kurhanewicz J., Vigneron D.B., Brindle K., et al. Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia 2011, 13(2):81-97.
63. Lardinois D., Weder W., Hany T.F., et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N. Engl. J. Med. 2003, 348(25):2500-2507.
64. 31P measurements of response to treatment. NMR Biomed. 1998, 11(7):314-340.
65. Li K.C., Guccione S., Bednarski M.D. Combined vascular targeted imaging and therapy: a paradigm for personalized treatment. J. Cell. Biochem. Suppl. 2002, 39:65-71.
66. Liao H., Shimaya K., Wang K., et al. Combination of intraoperative 5-aminolevulinic acid-induced fluorescence and 3-D MR imaging for guidance of robotic laser ablation for precision neurosurgery. Med. Image Comput. Comput. Assist. Interv. 2008, 11(2):373-380.
67. Lora-Michiels M., Yu D., Sanders L., et al. Extracellular pH and P-31 magnetic resonance spectroscopic variables are related to outcome in canine soft tissue sarcomas treated with thermoradiotherapy. Clin. Cancer Res. 2006, 12(19):5733-5740.
68. Lordick F., Ott K., Krause B.J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007, 8(9):797-805.
69. Macheda M.L., Rogers S., Best J.D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell Physiol. 2005, 202(3):654-662.
70. Madani I., Duthoy W., Derie C., et al. Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007, 68(1):126-135.
71. Majumder P.K., Febbo P.G., Bikoff R., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 2004, 10(6):594-601.
72. Mandrekar S.J., Sargent D.J. Predictive biomarker validation in practice: lessons from real trials. Clin. Trials 2010, 7(5):567-573.
73. Mankoff D.A., Link J.M., Linden H.M., Sundararajan L., Krohn K.A. Tumor receptor imaging. J. Nucl. Med. 2008, 49(Suppl. 2):149S-163S.
74. Moulick K., Ahn J.H., Zong H., et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat. Chem. Biol. 2011.
75. 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology 2001, 221(2):380-390.
76. Mueller-Lisse U.G., Swanson M.G., Vigneron D.B., et al. Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn. Reson. Med. 2001, 46(1):49-57.
77. Negri F., Musolino A., Cunningham D., Pastorino U., Ladas G., Norman A.R. Retrospective study of resection of pulmonary metastases in patients with advanced colorectal cancer: the development of a preoperative chemotherapy strategy. Clin. Colorectal Cancer 2004, 4(2):101-106.
78. Nelson S.J., Kurhanewicz J., Vigneron D.B. Magnetic resonance spectroscopy treatment response and detection. Molecular Imaging - Principles and Practice 2010, 896-911. People's Medical Publishing House, Shelton, CT, USA. first ed. R. Weissleder, B.D. Ross, A. Rehemtulla, S.S. Gambhir (Eds.).
79. Ohno Y., Koyama H., Onishi Y., et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment-utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 2008, 248(2):643-654.
80. Padhani A.R., Leach M.O. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom. Imaging 2005, 30(3):324-341.
81. Parivar F., Kurhanewicz J. Detection of recurrent prostate cancer after cryosurgery. Curr. Opin. Urol. 1998, 8(2):83-86.
82. Parivar F., Hricak H., Shinohara K., et al. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 1996, 48(4):594-599.
83. Patz E.F., Connolly J., Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am. J. Roentgenol. 2000, 174(3):769-774.
84. Peterson L.M., Mankoff D.A., Lawton T., Yagle K., Schubert E.K., Stekhova S., Gown A., Link J.M., Tewson T., Krohn K.A. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J. Nucl. Med. 2008, 49(3):367-374.
85. Pickett B., Kurhanewicz J., Coakley F., Shinohara K., Fein B., Roach M. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2004, 60(4):1047-1055.
86. Pieterman R.M., van Putten J.W., Meuzelaar J.J., et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N. Engl. J. Med. 2000, 343(4):254-261.
87. Pio B.S., Park C.K., Pietras R., et al. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol. Imaging Biol. 2006, 8(1):36-42.
88. Plathow C., Weber W.A. Tumor cell metabolism imaging. J. Nucl. Med. 2008, 49(Suppl. 2):43S-63S.
89. Rasey J.S., Grierson J.R., Wiens L.W., Kolb P.D., Schwartz J.L. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J. Nucl. Med. 2002, 43(9):1210-1217.
90. Rayson D., Bouttell E., Whiston F., Stitt L. Outcome after ovarian/adnexal metastectomy in metastatic colorectal carcinoma. J. Surg. Oncol. 2000, 75(3):186-192.
91. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J. Clin. Oncol. 2006, 24(13):2098-2104.
92. Rischin D., Peters L.J., O'Sullivan B., et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J. Clin. Oncol. 2010, 28(18):2989-2995.
93. Roach M., Kurhanewicz J., Carroll P. Spectroscopy in prostate cancer: hope or hype?. Oncol. (Williston Park) 2001, 15(11):1399-1410. Discussion 415-6, 418.
94. Sachs S., Bilfinger T.V. The impact of positron emission tomography on clinical decision making in a university-based multidisciplinary lung cancer practice. Chest 2005, 128(2):698-703.
95. Scher H.I., Beer T.M., Higano C.S., et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375(9724):1437-1446.
96. 18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J. Nucl. Med. 2010, 51(5):720-727.
97. Seam P., Juweid M.E., Cheson B.D. The role of FDG-PET scans in patients with lymphoma. Blood 2007, 110(10):3507-3516.
98. Shields A.F., Grierson J.R., Dohmen B.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med. 1998, 4(11):1334-1336.
99. Shu C.J., Campbell D.O., Lee J.T., et al. Novel PET probes specific for deoxycytidine kinase. J. Nucl. Med. 2010, 51(7):1092-1098.
100. Simcock B., Neesham D., Quinn M., Drummond E., Milner A., Hicks R.J. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol. Oncol. 2006, 103(1):271-276.
101. 31P NMR spectra from human breast tumours: variations in phospholipid metabolism. Br. J. Cancer 1991, 63(4):514-516.
102. Smith-Jones P.M., Solit D.B., Akhurst T., Afroze F., Rosen N., Larson S.M. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat. Biotechnol. 2004, 22(6):701-706.
103. Sostman H.D., Charles H.C., Rockwell S., et al. Soft-tissue sarcomas: detection of metabolic heterogeneity with P-31 MR spectroscopy. Radiology 1990, 176(3):837-843.
104. Strauss H.W., Blankenberg F., Vanderheyden J.L., Tait J. Translational imaging: imaging of apoptosis. Handbook Exp. Pharmacol. 2008, 185(Pt 2):259-275.
105. Stummer W., Reulen H.J., Meinel T., et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008, 62(3):564-576. Discussion -76.
106. Swirski F.K., Pittet M.J., Kircher M.F., et al. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc. Natl. Acad. Sci. USA 2006, 103(27):10340-10345.
107. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J. Nucl. Med. 2007, 48(5):726-735.
108. 18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity. J. Nucl. Med. 2010, 51(5):713-719.
109. Troyan S.L., Kianzad V., Gibbs-Strauss S.L., et al. The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann. Surg. Oncol. 2009, 16(10):2943-2952.
110. van Loon J., Offermann C., Bosmans G., et al. 18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study. Radiother. Oncol. 2008, 87(1):49-54.
111. 18F-FDG PET/CT. AJR Am. J. Roentgenol. 2011, 196(3):662-669.
112. Veach D.R., Namavari M., Pillarsetty N., et al. Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. J. Med. Chem. 2007, 50(23):5853-5857.
113. Viale A., Aime S. Current concepts on hyperpolarized molecules in MRI. Curr. Opin. Chem. Biol. 2010, 14(1):90-96.
114. von Schulthess G.K., Steinert H.C., Hany T.F. Integrated PET/CT: current applications and future directions. Radiology 2006, 238(2):405-422.
115. Warburg O., Wind F., Negelein E. The metabolism of tumors in the body. J. Gen. Physiol. 1927, 8(6):519-530.
116. Weber G. Enzymology of cancer cells (second of two parts). N. Engl. J. Med. 1977, 296(10):541-551.
117. Weber G. Enzymology of cancer cells (first of two parts). N. Engl. J. Med. 1977, 296(9):486-492.
118. Weber W.A. Positron emission tomography as an imaging biomarker. J. Clin. Oncol. 2006, 24(20):3282-3292.
119. Weissleder R., Pittet M.J. Imaging in the era of molecular oncology. Nature 2008, 452(7187):580-589.
120. Welch M.J., Hawker C.J., Wooley K.L. The advantages of nanoparticles for PET. J. Nucl. Med. 2009, 50(11):1743-1746.
121. Westphalen A.C., McKenna D.A., Kurhanewicz J., Coakley F.V. Role of magnetic resonance imaging and magnetic resonance spectroscopic imaging before and after radiotherapy for prostate cancer. J. Endourol. 2008, 22(4):789-794.
122. W N Studies of human tumors by MRS: a review. NMR Biomed. 1992, 5(5):303-324.
123. Zakian K.L., Hricak H., Ishill N., et al. An exploratory study of endorectal magnetic resonance imaging and spectroscopy of the prostate as preoperative predictive biomarkers of biochemical relapse after radical prostatectomy. J. Urol. 2010, 184(6):2320-2327.
124. Zavaleta C.L., Kircher M.F., Gambhir S.S. Raman's "effect" on molecular imaging. J. Nucl. Med. 2011, 52(12):1839-1844.
125. Zhao M., Kircher M.F., Josephson L., Weissleder R. Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug. Chem. 2002, 13(4):840-844.